NCT02531568

Drug Interaction Study of Warfarin and MT-3995

A Phase I, Open-label, Single-Centre, Drug-Drug Interaction Study to Evaluate the Influence of MT-3995 on Pharmacokinetics(PK) and Pharmacodynamics of Warfarin in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effects of MT-3995 on the PK of warfarin

Detailed description

The purpose of this study is to evaluate the potential effects of multiple once daily doses of MT-3995 on the PK of (S)-warfarin and (R)-warfarin after single-dose administration of racemic warfarin

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Warfarin
DRUG	MT-3995

Timeline

• Start date: 2015-06-01
• Primary completion: 2015-08-01
• Completion: 2015-09-01
• First posted: 2015-08-24
• Last updated: 2015-10-09

Locations

1 site across 1 country: Germany